Stockreport

Sana Biotechnology: Scope Goes Beyond HIP-Modified Pancreatic Islet Cells For T1D [Seeking Alpha]

Sana Biotechnology, Inc.  (SANA) 
PDF Sana Biotechnology's HIP-modified islet cell therapy showed a 6-month insulin response without needing immunosuppression in one T1D patient, supporting a paradigm shift [Read more]